TBX2 is preferentially amplified in BRCA1- and BRCA2-related breast tumors.
TBX2 is preferentially amplified in BRCA1- and BRCA2-related breast tumors.
复制标题
DOI：
--
复制
发表时间：
2002-07
期刊：
影响因子：
11.2
通讯作者：
Colleen S. Sinclair;C. Adem;A. Naderi;Cheryl L. Soderberg;Michele R Johnson;Kangjian Wu;Linda Wadum;V. Couch;T. Sellers;D. Schaid;J. Slezak;Z. Fredericksen;J. Ingle;L. Hartmann;R. Jenkins;F. Couch
中科院分区：
文献类型：
--
作者：
Colleen S. Sinclair;C. Adem;A. Naderi;Cheryl L. Soderberg;Michele R Johnson;Kangjian Wu;Linda Wadum;V. Couch;T. Sellers;D. Schaid;J. Slezak;Z. Fredericksen;J. Ingle;L. Hartmann;R. Jenkins;F. Couch
染色体17q23区域在乳腺肿瘤中经常扩增。50%的BRCA1相关乳腺肿瘤和87%的BRCA2相关乳腺肿瘤中存在该区域的增益。在27例BRCA 1和BRCA 2突变型乳腺肿瘤、15例无BRCA 1或BRCA 2突变的高危患者乳腺肿瘤和62例匹配的散发性乳腺肿瘤对照中，比较了该扩增子中RPS6KB 1和TBX 2癌基因的扩增频率。TBX2在BRCA 1和BRCA 2突变肿瘤中被确定为优先扩增和过表达，而RPS6KB 1则没有，这表明TBX2扩增在BRCA 1和BRCA 2相关乳腺肿瘤的发展中起作用。
The chromosome 17q23 region is frequently amplified in breast tumors. Gain of the region is present in 50% of BRCA1-associated breast tumors and 87% of BRCA2-associated breast tumors. The amplification frequency of the RPS6KB1 and TBX2 oncogenes from this amplicon was compared in 27 BRCA1 and BRCA2 mutant breast tumors, 15 breast tumors from high-risk patients with no BRCA1 or BRCA2 mutations, and 62 matched sporadic breast tumor controls. TBX2 was determined to be preferentially amplified and overexpressed in BRCA1 and BRCA2 mutant tumors, whereas RPS6KB1 was not, suggesting a role for TBX2 amplification in the development of BRCA1- and BRCA2-associated breast tumors.